Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvortuxizumab in Relapsed or Refractory B-cell Malignancies
NCT02454270Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Jul 2018
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of duvortuxizumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 2 more (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Recommended Phase 2 Dose at 15 months and Overall Response Rate at 2 years. Started Jun 2015; status: terminated.
02
Drugs
duvortuxizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02454270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454270.